In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
ASA Gold and Precious Metals Ltd. shareholders voted at a special meeting last week to enlarge the closed-end fund's board and elected a fifth independent director, one ...
Members of the Heartland Funds board and Heartland Advisors management team spent a recent evening together sharing a meal. Of course it's not unusual for independent ...
Average compensation among mutual fund independent directors was higher in 2024, when compared to the year prior, an increase that was more than double what their ...
Comprehensive guidance on the oversight of sub-advisers that exists in the market has served mutual fund boards well for over 15 years. These frameworks remain foundational, ...